Table 3.
Patient demographics and operative details
| Categorical variable | ERAS patients, n= 50 |
|---|---|
| Age, years, median (IQR) | 67 (55–73) |
| Gender, male, n (%) | 24 (48%) |
| Indication for PD, n (%)a | |
| Head of pancreas carcinoma | 26 (52%) |
| Ampullary carcinoma | 16 (32%) |
| Distal CBD carcinoma | 3 (6%) |
| Endocrine neoplasm | 1 (2%) |
| Chronic pancreatitis | 0 |
| Other | 4 (8%) |
| Procedure, n (%) | |
| Classical PD | 42 (84%) |
| Pylorus-preserving PD | 6 (12%) |
| PD with SMV or portal vein resection | 2 (4%) |
| Duration of surgery, min, median (IQR)a | 360 (310–420) |
| Estimated theatre blood loss, ml, median (IQR)a | 1000 (604–1275) |
a
Data available for 48 patients.
ERAS, enhanced recovery after surgery; IQR, interquartile range; PD, pancreaticoduodenectomy; CBD, common bile duct; SMV, superior mesenteric vein.